MXPA03004290A - Metodos de tratamiento de condiciones asociadas con cinasa p38 y compuestos de pirrolotirazina utiles como inhibidores de cinasa. - Google Patents

Metodos de tratamiento de condiciones asociadas con cinasa p38 y compuestos de pirrolotirazina utiles como inhibidores de cinasa.

Info

Publication number: MXPA03004290A
Authority: MX; Mexico
Prior art keywords: kinase; treating; methods; compounds useful; associated conditions
Prior art date: 2000-11-17

Application number

MXPA03004290A

Other languages

English (en)

Inventor

Katerina Leftheris

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-17

Filing date

2001-11-07

Publication date

2004-02-12

2001-11-07 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2004-02-12 Publication of MXPA03004290A publication Critical patent/MXPA03004290A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Obesity (AREA)
Transplantation (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)

MXPA03004290A 2000-11-17 2001-11-07 Metodos de tratamiento de condiciones asociadas con cinasa p38 y compuestos de pirrolotirazina utiles como inhibidores de cinasa. MXPA03004290A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US24987700P	2000-11-17	2000-11-17
US31056101P	2001-08-07	2001-08-07
PCT/US2001/049982 WO2002040486A2 (en)	2000-11-17	2001-11-07	METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS

Publications (1)

Publication Number	Publication Date
MXPA03004290A true MXPA03004290A (es)	2004-02-12

Family

ID=26940426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03004290A MXPA03004290A (es)	2000-11-17	2001-11-07	Metodos de tratamiento de condiciones asociadas con cinasa p38 y compuestos de pirrolotirazina utiles como inhibidores de cinasa.

Country Status (31)

Country	Link
EP (1)	EP1363910B1 (es)
JP (1)	JP2004522713A (es)
KR (1)	KR100847605B1 (es)
CN (1)	CN1622946A (es)
AR (1)	AR032637A1 (es)
AT (1)	ATE318820T1 (es)
AU (2)	AU3276002A (es)
BG (1)	BG107750A (es)
BR (1)	BR0115446A (es)
CA (1)	CA2429628A1 (es)
CY (1)	CY1105250T1 (es)
CZ (1)	CZ20031370A3 (es)
DE (1)	DE60117607T2 (es)
DK (1)	DK1363910T3 (es)
EE (1)	EE200300227A (es)
ES (1)	ES2259051T3 (es)
GE (1)	GEP20063915B (es)
HR (1)	HRP20030485A2 (es)
HU (1)	HUP0303897A2 (es)
IL (1)	IL155570A0 (es)
IS (1)	IS6816A (es)
MX (1)	MXPA03004290A (es)
MY (1)	MY127066A (es)
NO (1)	NO20032229L (es)
NZ (1)	NZ525334A (es)
PE (1)	PE20020819A1 (es)
PL (1)	PL366376A1 (es)
PT (1)	PT1363910E (es)
SK (1)	SK5402003A3 (es)
WO (1)	WO2002040486A2 (es)
YU (1)	YU37903A (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6867300B2 (en)	2000-11-17	2005-03-15	Bristol-Myers Squibb Company	Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
DK1401416T5 (da)	2001-06-29	2007-03-19	Ab Science	Anvendelse af C-kit-inhibitorer til behandling af inflammatorisk tarmsygdom
EP1401411A2 (en) *	2001-06-29	2004-03-31	AB Science	Use of tyrosine kinase inhibitors for treating bone loss
ATE376182T1 (de)	2001-06-29	2007-11-15	Ab Science	C-kit inhibitoren
JP2004537536A (ja)	2001-06-29	2004-12-16	アブサイエンス	アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
DK1401415T3 (da)	2001-06-29	2006-10-16	Ab Science	Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
GB0124931D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124934D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124936D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124938D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124939D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124941D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
GB0124933D0 (en)	2001-10-17	2001-12-05	Glaxo Group Ltd	Chemical compounds
PL212910B1 (pl)	2002-02-12	2012-12-31	Smithkline Beecham Corp	Pochodna nikotynoamidu, srodek farmaceutyczny i zastosowanie pochodnej nikotynoamidu
JP4164031B2 (ja)	2002-02-14	2008-10-08	ファルマシアコーポレーション	Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン
US6900208B2 (en)	2002-03-28	2005-05-31	Bristol Myers Squibb Company	Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2003221753A1 (en)	2002-04-23	2003-11-10	Bristol-Myers Squibb Company	Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US7388009B2 (en)	2002-04-23	2008-06-17	Bristol-Myers Squibb Company	Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
JP4669225B2 (ja) *	2002-04-23	2011-04-13	ブリストル−マイヤーズスクイブカンパニー	キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物
US6933386B2 (en) *	2002-07-19	2005-08-23	Bristol Myers Squibb Company	Process for preparing certain pyrrolotriazine compounds
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
GB0217757D0 (en)	2002-07-31	2002-09-11	Glaxo Group Ltd	Novel compounds
EP1543009A4 (en)	2002-08-02	2007-08-08	Bristol Myers Squibb Co	Pyrrolotriazine KINASE INHIBITORS
TW200420565A (en) *	2002-12-13	2004-10-16	Bristol Myers Squibb Co	C-6 modified indazolylpyrrolotriazines
MXPA05007462A (es) *	2003-01-09	2006-01-27	Astellas Pharma Inc	Derivados de pirrolopiridazina.
BRPI0407282A (pt) *	2003-02-05	2006-01-31	Bristol Myers Squibb Co	Processo para preparação de inibidores de pirrolotriazina cinase
GB0308186D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308185D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
GB0308201D0 (en)	2003-04-09	2003-05-14	Smithkline Beecham Corp	Novel compounds
ATE439837T1 (de)	2003-06-03	2009-09-15	Novartis Ag	5-gliedrige heterocyclische p-38 inhibitoren
PT1641764E (pt)	2003-06-26	2011-10-27	Novartis Ag	Inibidores de p38 quinase a base de heterociclo de 5 elementos
ES2315703T3 (es)	2003-07-25	2009-04-01	Novartis Ag	Inhibidores de la quinasa p-38.
GB0318814D0 (en)	2003-08-11	2003-09-10	Smithkline Beecham Corp	Novel compounds
US7419978B2 (en) *	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US7102001B2 (en) *	2003-12-12	2006-09-05	Bristol-Myers Squibb Company	Process for preparing pyrrolotriazine
JP2007517052A (ja) *	2003-12-23	2007-06-28	ノバルティスアクチエンゲゼルシャフト	二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
US7064203B2 (en)	2003-12-29	2006-06-20	Bristol Myers Squibb Company	Di-substituted pyrrolotriazine compounds
MY145634A (en)	2003-12-29	2012-03-15	Bristol Myers Squibb Co	Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
UY28931A1 (es) *	2004-06-03	2005-12-30	Bayer Pharmaceuticals Corp	Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7102002B2 (en)	2004-06-16	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US7173031B2 (en) *	2004-06-28	2007-02-06	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7102003B2 (en)	2004-07-01	2006-09-05	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7504521B2 (en)	2004-08-05	2009-03-17	Bristol-Myers Squibb Co.	Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (es)	2004-08-12	2006-06-01	Bristol Myers Squibb Co	Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
US7151176B2 (en)	2004-10-21	2006-12-19	Bristol-Myers Squibb Company	Pyrrolotriazine compounds
US7855288B2 (en)	2004-10-26	2010-12-21	Novartis Ag	Pyrrolo [1,2-d] [1,2-4] triazine as inhibitors of c-Jun N terminal kinases (JNK) and p-38 kinases
US7402582B2 (en) *	2005-07-01	2008-07-22	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) *	2005-07-01	2008-07-29	Bristol-Myers Squibb Company	Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007035428A1 (en)	2005-09-15	2007-03-29	Bristol-Myers Squibb Company	Met kinase inhibitors
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
US7514435B2 (en)	2005-11-18	2009-04-07	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US7348325B2 (en)	2005-11-30	2008-03-25	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
US8063208B2 (en)	2006-02-16	2011-11-22	Bristol-Myers Squibb Company	Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
US8268998B2 (en)	2006-11-03	2012-09-18	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
JP5180967B2 (ja) *	2006-11-03	2013-04-10	ブリストル−マイヤーズスクイブカンパニー	ピロロトリアジンキナーゼ阻害剤
AR074830A1 (es)	2008-12-19	2011-02-16	Cephalon Inc	Pirrolotriazinas como inhibidores de alk y jak2
US20120035177A1 (en) *	2009-04-16	2012-02-09	Bristol-Myers Squibb Company	Tablet formulation for p38 inhibitor and method
KR20130083389A (ko) *	2010-05-28	2013-07-22	바이오크리스트파마슈티컬즈,인코포레이티드	야누스 키나아제 억제제로서 헤테로사이클릭 화합물
CN103012439B (zh) *	2012-11-15	2015-03-11	沈阳药科大学	苯甲酰基取代的噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
EP2970295B1 (en) *	2013-03-11	2016-12-28	Bristol-Myers Squibb Company	Pyrrolopyridazines as potassium ion channel inhibitors
US9403834B2 (en) *	2013-03-11	2016-08-02	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
US9050345B2 (en) *	2013-03-11	2015-06-09	Bristol-Myers Squibb Company	Pyrrolotriazines as potassium ion channel inhibitors
WO2015054358A1 (en)	2013-10-11	2015-04-16	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
WO2015081783A1 (zh) *	2013-12-06	2015-06-11	江苏奥赛康药业股份有限公司	吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3691620B1 (en)	2017-10-05	2022-07-27	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
CN108516977A (zh) *	2018-07-10	2018-09-11	刘凤娟	一种用于治疗恶性肿瘤的map激酶抑制剂的合成方法
CN112028892B (zh) *	2020-07-29	2022-12-16	天津全和诚科技有限责任公司	4-氨基-吡咯并三嗪衍生物在制备抗肺纤维化制剂中的应用
CN112094219B (zh) *	2020-09-10	2022-08-05	广东莱佛士制药技术有限公司	一种制备钾离子竞争性阻滞剂中间体的方法
CN119365460A (zh)	2022-04-08	2025-01-24	尚医治疗有限责任公司	与Ras超家族蛋白相互作用以用于治疗癌症、炎性疾病、RAS病和纤维化疾病的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2163399A1 (en) *	1994-11-24	1996-05-25	Katsuhiro Kawano	Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
WO1999024033A1 (en) *	1997-11-12	1999-05-20	Shionogi & Co., Ltd.	Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU770377B2 (en) *	1999-05-21	2004-02-19	Bristol-Myers Squibb Company	Pyrrolotriazine inhibitors of kinases

2001
- 2001-11-07 HR HR20030485A patent/HRP20030485A2/hr not_active Application Discontinuation
- 2001-11-07 IL IL15557001A patent/IL155570A0/xx unknown
- 2001-11-07 AT AT01992298T patent/ATE318820T1/de not_active IP Right Cessation
- 2001-11-07 MX MXPA03004290A patent/MXPA03004290A/es active IP Right Grant
- 2001-11-07 YU YU37903A patent/YU37903A/sh unknown
- 2001-11-07 AU AU3276002A patent/AU3276002A/xx active Pending
- 2001-11-07 WO PCT/US2001/049982 patent/WO2002040486A2/en not_active Ceased
- 2001-11-07 SK SK540-2003A patent/SK5402003A3/sk unknown
- 2001-11-07 EP EP01992298A patent/EP1363910B1/en not_active Expired - Lifetime
- 2001-11-07 CZ CZ20031370A patent/CZ20031370A3/cs unknown
- 2001-11-07 NZ NZ525334A patent/NZ525334A/en unknown
- 2001-11-07 DE DE60117607T patent/DE60117607T2/de not_active Expired - Lifetime
- 2001-11-07 HU HU0303897A patent/HUP0303897A2/hu unknown
- 2001-11-07 CN CNA018189970A patent/CN1622946A/zh active Pending
- 2001-11-07 KR KR1020037006661A patent/KR100847605B1/ko not_active Expired - Fee Related
- 2001-11-07 BR BR0115446-0A patent/BR0115446A/pt not_active IP Right Cessation
- 2001-11-07 AU AU2002232760A patent/AU2002232760B2/en not_active Ceased
- 2001-11-07 CA CA002429628A patent/CA2429628A1/en not_active Abandoned
- 2001-11-07 PL PL01366376A patent/PL366376A1/xx not_active Application Discontinuation
- 2001-11-07 DK DK01992298T patent/DK1363910T3/da active
- 2001-11-07 ES ES01992298T patent/ES2259051T3/es not_active Expired - Lifetime
- 2001-11-07 EE EEP200300227A patent/EE200300227A/xx unknown
- 2001-11-07 PT PT01992298T patent/PT1363910E/pt unknown
- 2001-11-07 GE GE5243A patent/GEP20063915B/en unknown
- 2001-11-07 JP JP2002543494A patent/JP2004522713A/ja active Pending
- 2001-11-13 MY MYPI20015207A patent/MY127066A/en unknown
- 2001-11-16 PE PE2001001141A patent/PE20020819A1/es not_active Application Discontinuation
- 2001-11-16 AR ARP010105381A patent/AR032637A1/es unknown
2003
- 2003-04-21 BG BG107750A patent/BG107750A/bg unknown
- 2003-05-14 IS IS6816A patent/IS6816A/is unknown
- 2003-05-16 NO NO20032229A patent/NO20032229L/no not_active Application Discontinuation
2006
- 2006-06-01 CY CY20061100698T patent/CY1105250T1/el unknown

Also Published As

Publication number	Publication date
NZ525334A (en)	2005-07-29
AU3276002A (en)	2002-05-27
KR20030045195A (ko)	2003-06-09
HUP0303897A2 (hu)	2004-03-01
EP1363910A2 (en)	2003-11-26
SK5402003A3 (en)	2004-06-08
PE20020819A1 (es)	2002-09-11
NO20032229L (no)	2003-07-16
MY127066A (en)	2006-11-30
CZ20031370A3 (cs)	2003-10-15
DE60117607D1 (de)	2006-04-27
BG107750A (bg)	2004-01-30
HK1057555A1 (en)	2004-04-08
GEP20063915B (en)	2006-09-11
EE200300227A (et)	2003-10-15
PT1363910E (pt)	2006-05-31
BR0115446A (pt)	2005-08-09
AU2002232760C1 (en)	2002-05-27
WO2002040486A2 (en)	2002-05-23
EP1363910B1 (en)	2006-03-01
KR100847605B1 (ko)	2008-07-21
IS6816A (is)	2003-05-14
CY1105250T1 (el)	2010-03-03
PL366376A1 (en)	2005-01-24
CA2429628A1 (en)	2002-05-23
IL155570A0 (en)	2003-11-23
HRP20030485A2 (en)	2004-08-31
JP2004522713A (ja)	2004-07-29
ATE318820T1 (de)	2006-03-15
DK1363910T3 (da)	2006-06-26
DE60117607T2 (de)	2007-01-25
CN1622946A (zh)	2005-06-01
NO20032229D0 (no)	2003-05-16
ES2259051T3 (es)	2006-09-16
AU2002232760B2 (en)	2006-12-14
YU37903A (sh)	2006-05-25
AR032637A1 (es)	2003-11-19
WO2002040486A3 (en)	2003-09-12

Publication	Publication Date	Title
MXPA03004290A (es)	2004-02-12	Metodos de tratamiento de condiciones asociadas con cinasa p38 y compuestos de pirrolotirazina utiles como inhibidores de cinasa.
EG24027A (en)	2008-03-26	Pyrrolotriazine inhibitors of kinases
AU2002248269A1 (en)	2002-08-12	Use of p38 inhibitors for the treatment of inflammation-enhanced cough
EP1363702A4 (en)	2007-08-22	PROCESS FOR INHIBITING KINASES
MXPA03007960A (es)	2003-12-04	Compuestos y metodos para el tratamiento de desordenes urogenitales.
ZA200206034B (en)	2003-07-29	Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes.
AU2000240570A1 (en)	2001-10-08	Pyrrolopyrimidines as tyrosine kinase inhibitors
AP2006003708A0 (en)	2006-08-31	Methods and compositions for treating flavivirusesand pestiviruses
WO2005054246A3 (de)	2005-07-28	Aminderivate mit tyrosinkinase hemmender wirkung
PL369237A1 (en)	2005-04-18	Micro-organisms for the treatment of soil and process for obtaining them
ZA200206612B (en)	2004-02-19	Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction.
WO2002030353A3 (en)	2002-06-27	NF-λB INHIBITORS
AU8647801A (en)	2002-04-08	Methods of providing and using compounds having activity as inhibitors of cytochrome p450rai
AU2003283958A8 (en)	2004-04-30	Method of treating tremors
HUP0303034A3 (en)	2012-12-28	Novel 7-azaindole-derivatives, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
AU2002232400A1 (en)	2002-05-15	Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
MXPA02012907A (es)	2003-09-22	Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxia de la obesidad.
PL368948A1 (en)	2005-04-04	Process and composition for treating wood
WO2002076396A3 (en)	2002-12-19	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2000064422A3 (en)	2001-03-01	Novel treatment of neurotraumatic conditions with raf inhibitor
SI1363910T1 (sl)	2006-08-31	Postopki zdravljenja s P38 kinazo povezanih stanjin pirolotriazinske spojine, uporabne kot inhibitorji kinaze
EP1383505A4 (en)	2006-08-09	INOSIN COMPOUNDS AND USES THEREOF FOR THE TREATMENT OR PREVENTION OF INFLAMMATION OR REPERFUSION DISEASE
IL161630A0 (en)	2004-09-27	Methods of treating endometreosis
AU2002342715A1 (en)	2002-11-25	Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
WO2001087305A3 (en)	2002-04-25	Method for treating functional dyspepsia using alosetron

Legal Events

Date	Code	Title	Description
2006-05-03	FG	Grant or registration